Neoplasm, Lymphatic Tissue: Clinical Trials

12 trials for Neoplasm, Lymphatic Tissue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 12 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Completed 8, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 26Completed 4, Active not recruiting 1, Recruiting 1

Follow Neoplasm, Lymphatic Tissue: new trials by email Literature Review of Neoplasm, Lymphatic Tissue trials Research Report on Neoplasm, Lymphatic Tissue

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Imatimib Mesylate, Placebo - Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Phase 1RecruitingColumbia University202025-10-202026-01-21
Feasibility of [11C]Acetate-PET in LAM and TSC
[11C]acetate - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2Active not recruitingBrigham and Women's Hospital72021-08-302026-01-21
Glutamine PET Imaging in LAM
Glutamine - Lymphangioleiomyomatosis (LAM)
Phase 1CompletedVanderbilt University Medical Center52019-10-182021-08-11
LAM Pilot Study With Imatinib Mesylate
Imatinib Mesylate 400Mg Capsule, Placebo - Capsule - Lymphangioleiomyomatosis
Phase 1 / Phase 2CompletedMedical University of South Carolina182018-01-232020-06-16
The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Saracatinib - Pulmonary Lymphangioleiomyomatosis
Phase 1CompletedTony Eissa92014-08-012016-11-30
Safety of Simvastatin in LAM and TSC
Simvastatin, Sirolimus Oral Product, Everolimus Oral Product - Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Phase 1 / Phase 2CompletedUniversity of Pennsylvania102014-03-012020-08-25
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
albuterol inhaler, albuterol nebulizer, PFT - Lymphangioleiomyomatosis
Phase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)1002013-06-102026-11-18
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease
Phase 1TerminatedM.D. Anderson Cancer Center1162012-10-162026-11-05
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
"Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg - Lymphangioleiomyomatosis
Phase 1CompletedBrigham and Women's Hospital142012-09-012018-10-11
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Sildenafil - Lymphangioma
Phase 1 / Phase 2CompletedStanford University72010-12-012015-06-19
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
belinostat, 5-Fluorouracil (5-FU) - Tumor
Phase 1CompletedValerio Therapeutics352005-09-012015-07-08
RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
RAD001 - Tuberous Sclerosis, Lymphangioleiomyomatosis
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati362005-08-012013-09-25

Narrower conditions

Lymphangioleiomyomatosis (10)  ·  Tuberous Sclerosis (3)  ·  Breast Neoplasms (2)  ·  Mouth Neoplasms (2)  ·  Neoplasms (2)  ·  Sarcoma (2)  ·  Thyroid Neoplasms (2)  ·  Adenosarcoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Small Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Carcinosarcoma (1)  ·  Castleman Disease (1)  ·  Chondrosarcoma (1)

Broader conditions

Neoplasms by Histologic Type (12)  ·  Hemic and Lymphatic Diseases (11)  ·  Lymphatic Diseases (11)  ·  Neoplasms, Connective and Soft Tissue (11)  ·  Immune System Diseases (10)  ·  Immunoproliferative Disorders (10)  ·  Lymphangiomyoma (10)  ·  Lymphoproliferative Disorders (10)  ·  Neoplasms (10)  ·  Perivascular Epithelioid Cell Neoplasms (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Congenital Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Heredodegenerative Disorders, Nervous System (4)

Interventions

Sirolimus (3)  ·  Everolimus (2)  ·  Imatinib Mesylate (2)  ·  Bevacizumab (1)  ·  Cetuximab (1)  ·  Disulfides (1)  ·  Fluorouracil (1)  ·  Glutamine (1)  ·  Hydroxychloroquine (1)  ·  Immunoglobulin G (1)  ·  Sildenafil Citrate (1)  ·  Simvastatin (1)  ·  Valproic Acid (1)  ·  belinostat (1)  ·  carbon-11 acetate (1)

Sponsors

Brigham and Women's Hospital (2)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Columbia University (1)  ·  M.D. Anderson Cancer Center (1)  ·  Medical University of South Carolina (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  Stanford University (1)  ·  Tony Eissa (1)  ·  University of Pennsylvania (1)  ·  Valerio Therapeutics (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (12)

Top investigators

Frank McCormack, MD (2)  ·  Alfred T Lane, MD (1)  ·  Carmen P Priolo, MD PhD (1)  ·  Christopher Meinberg (1)  ·  Elizabeth P Henske, MD (1)  ·  Jeanine D'Armiento, MD, PhD (1)  ·  Joel Moss, M.D. (1)  ·  Joel Moss, MD, PhD (1)  ·  John J. Bissler, M.D. (1)  ·  Khalid Almoosa, MD (1)  ·  Maryl Kreider, MD, MSCE (1)  ·  Nicola A Hanania, MD (1)  ·  Sarina A Piha-Paul (1)  ·  Timothy S Blackwell, MD (1)  ·  Tony Eissa, MD (1)

Results publications

PMID 21482669, PMID 24656411, PMID 26933802, PMID 28192114, PMID 30144422, PMID 31299246, PMID 37311055, PMID 41389341

NIH funding

1ZIAHL002541-21 (1), UL1TR000093 (1)